High-Dose Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration Resistant to Standard-Dose Brolucizumab
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
High-Dose Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration Resistant to Standard-Dose Brolucizumab ; volume:13 ; number:10 ; day:30 ; month:8 ; year:2024 ; pages:2789-2797 ; date:10.2024
Ophthalmology and therapy ; 13, Heft 10 (30.8.2024), 2789-2797, 10.2024
- Creator
-
Kim, Jinsoo
Park, Min Seon
Cho, Bum-Joo
Kwon, Soonil
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40123-024-01022-w
- URN
-
urn:nbn:de:101:1-2411302120474.783851753528
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:25 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kim, Jinsoo
- Park, Min Seon
- Cho, Bum-Joo
- Kwon, Soonil
- SpringerLink (Online service)
Other Objects (12)
Double-dose investigation of aflibercept in neovascular age-related macular degeneration (DIANA): a real-world study
High-dose Methotrexate
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
Safety and Efficacy of Multiple Escalating Doses of RC28-E for Neovascular Age-Related Macular Degeneration: A Phase 1b Trial
Near-infrared reflectance imaging of neovascular age-related macular degeneration
Mineralocorticoid Antagonists as Adjuncts in Neovascular Age-Related Macular Degeneration
Efficacy and safety of abicipar in neovascular age-related macular degeneration
Vision protection therapy for prevention of neovascular age-related macular degeneration
Treatment of age-related neovascular macular degeneration: the patient’s perspective
Is There a Dose-Response Relationship? Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Treatment in Neovascular Age-Related Macular Degeneration
Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
Double-dose investigation of aflibercept in neovascular age-related macular degeneration (DIANA): a real-world study
High-dose Methotrexate
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
Safety and Efficacy of Multiple Escalating Doses of RC28-E for Neovascular Age-Related Macular Degeneration: A Phase 1b Trial
Near-infrared reflectance imaging of neovascular age-related macular degeneration
Mineralocorticoid Antagonists as Adjuncts in Neovascular Age-Related Macular Degeneration
Efficacy and safety of abicipar in neovascular age-related macular degeneration
Vision protection therapy for prevention of neovascular age-related macular degeneration
Treatment of age-related neovascular macular degeneration: the patient’s perspective
Is There a Dose-Response Relationship? Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Treatment in Neovascular Age-Related Macular Degeneration
Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
Double-dose investigation of aflibercept in neovascular age-related macular degeneration (DIANA): a real-world study
High-dose Methotrexate
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
Safety and Efficacy of Multiple Escalating Doses of RC28-E for Neovascular Age-Related Macular Degeneration: A Phase 1b Trial
Near-infrared reflectance imaging of neovascular age-related macular degeneration
Mineralocorticoid Antagonists as Adjuncts in Neovascular Age-Related Macular Degeneration
Efficacy and safety of abicipar in neovascular age-related macular degeneration
Vision protection therapy for prevention of neovascular age-related macular degeneration
Treatment of age-related neovascular macular degeneration: the patient’s perspective
Is There a Dose-Response Relationship? Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Treatment in Neovascular Age-Related Macular Degeneration